Monoclonal antibodies (mAbs) have naturally evolved as suitable, high affinity and specificity targeting molecules. However, the large size of full-length mAbs yields poor pharmacokinetic properties. A solution to this issue is the use of a multistep administration approach, in which the slower clearing mAb is administered first and allowed to reach the target site selectively, followed by administration of a rapidly clearing small molecule carrier of the cytotoxic or imaging ligand, which bears a cognate receptor for the mAb. Here, we introduce a novel pretargetable RNA based system comprised of locked nucleic acids (LNA) and 2′O-Methyloligoribonucleotides (2′OMe-RNA). The duplex shows fast hybridization, high melting temperatures, excellent affinity, and high nuclease stability in plasma. Using a prototype model system with rituximab conjugated to 2′OMe-RNA (oligo), we demonstrate that LNA-based complementary strand (c-oligo) effectively hybridizes with rituximab–oligo, which is slowly circulating in vivo, despite the high clearance rates of c-oligo.
BEIJERB., SULSTONI., SPROATB.S., RIDERP., LAMONDA.I., NEUNERP. 1990. Synthesis and applications of oligoribonucleotides with selected 2′-O-methylation using the 2′-O-[1-(2-fluorophenyl)-4-methoxypiperidin-4-yl] protecting group. Nucleic Acids Res, 18:5143–551.
3.
BHATTACHARYYAJ., MAITIS., MUHURIS., NAKANOS., MIYOSHID., SUGIMOTON.2011. Effect of locked nucleic acid modifications on the thermal stability of noncanonical DNA structure. Biochemistry, 50:7414–7425.
4.
BOSE.S., KUIJPERSW.H., MEESTERS-WINTERSM., PHAMD.T., DE HAANA.S., VAN DOORNMALENA.M., KASPERSENF.M., VAN BOECKELC.A., GOUGEON-BERTRANDF.1994. In vitro evaluation of DNA-DNA hybridization as a two-step approach in radioimmunotherapy of cancer. Cancer Res., 54:3479–3486.
5.
BOSWELLC.A., BRECHBIELM.W.2007. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl. Med. Biol., 34:757–778.
6.
DALPKEA., HELMM.2012. RNA mediated Toll-like receptor stimulation in health and disease. RNA Biol., 9:828–942.
7.
FLUITERK., FRIEDENM., VREIJLINGJ., ROSENBOHMC., DE WISSELM.B., CHRISTENSENS.M., KOCHT., ORUMH., BAASF.2005. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. Chembiochem., 6:1104–1109.
8.
GOLDENBERGD.M., CHATALJ.F., BARBETJ., BOERMANO., SHARKEYR.M.2007. Cancer imaging and therapy with bispecific antibody pretargeting. Update. Cancer Ther., 2:19–31.
9.
GREEND.J., PAGELJ.M., NEMECEKE.R., LINY., KENOYERA., PANTELIASA., HAMLIND.K., WILBURD.S., FISHERD.R., RAJENDRANJ.G.et al.2009. Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates. Blood, 114:1226–1235.
10.
HNATOWICD.J., NAKAMURAK.2006. The influence of chemical structure of DNA and other oligomer radiopharmaceuticals on tumor delivery. Curr. Opin. Mol. Ther., 8:136–143.
11.
HUGHESB.2010. Antibody-drug conjugates for cancer: poised to deliver? Nat. Rev. Drug Discov., 9:665–667.
12.
IRIBARRENA.M., SPROATB.S., NEUNERP., SULSTONI., RYDERU., LAMONDA.I.1990. 2′-O-alkyl oligoribonucleotides as antisense probes. Proc. Natl. Acad. Sci. U. S. A., 87:7747–7751.
13.
JESPERW.1999. Synthesis of 3′-C- and 4′-C-branched oligodeoxynucleotides and the development of locked nucleic Acid (LNA)Acc. Chem. Res., 32:301–310.
14.
KARACAYH., SHARKEYR.M., GOVINDANS.V., MCBRIDEW.J., GOLDENBERGD.M., HANSENH.J., GRIFFITHSG.L.1997. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent development. Bioconjug. Chem., 8:585–594.
15.
KAURH., BABUB.R., MAITIS.2007. Perspectives on chemistry and therapeutic applications of Locked Nucleic Acid (LNA)Chem. Rev., 107:4672–4697.
LIUG., MANG'ERAK., LIUN., GUPTAS., RUSCKOWSKIM., HNATOWICHD.J.2002b. Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog. J. Nucl. Med., 43:384–391.
MOSCHOSS.A., FRICKM., TAYLORB., TURNPENNYP., GRAVESH., SPINKK.G., BRADYK., LAMBD., COLLINSD., ROCKELT.D.et al.2011. Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense. Mol. Ther., 19:2163–2168.
24.
OLAFSENT., KENANOVAV.E., WUA.M.2006. Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat. Protoc., 1:2048–2060.
25.
OWCZARZYR., TATAUROVA.V., WUY., MANTHEYJ.A., MCQUISTENK.A., ALMABRAZIH.G., PEDERSENK.F., LINY., GARRETSONJ., MCENTAGGARTN.O.et al.2008. IDT SciTools: a suite for analysis and design of nucleic acid oligomers. Nucleic Acids Res., 36:W163–W169.
SHARKEYR.M., CHANGC.H., ROSSIE.A., MCBRIDEW.J., GOLDENBERGD.M.2012. Pretargeting: taking an alternate route for localizing radionuclides. Tumour Biol., 33:591–600.
29.
SHARKEYR.M., GOLDENBERGD.M.2011. Cancer radioimmunotherapy. Immunotherapy, 3:349–370.
30.
SUMMERTONJ., WELLERD.1997. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev., 7:187–195.
31.
SUNM.M., BEAMK.S., CERVENYC.G., HAMBLETTK.J., BLACKMORER.S., TORGOVM.Y., HANDLEYF.G., IHLEN.C., SENTERP.D., ALLEYS.C.2005. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug. Chem., 16:1282–1290.
32.
VILLAC.H., MCDEVITTM.R., ESCORCIAF.E., REYD.A., BERGKVISTM., BATTC.A., SCHEINBERGD.A.2008. Synthesis and biodistribution of oligonucleotide-functionalized, tumor-targetable carbon nanotubes. Nano Lett., 8:4221–4228.
33.
ZEGLISB.M., MOHINDRAP., WEISSMANNG.I., DIVILOVV., HILDERBRANDS.A., WEISSLEDERR., LEWISJ.S.2011. Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels-Alder click chemistry. Bioconjug. Chem., 22:2048–2059.
34.
ZUKERM.2003. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res., 31:3406–3415.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
